Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Monoclonal Gammopathy of Undetermined Significance
100%
Myeloma Cells
100%
Multiple Myeloma
100%
Plasma Cells
75%
B Cells
75%
Fibroblast Growth Factor 1 (FGF1)
62%
Treatment Strategy
37%
Heparan Sulfate Proteoglycans
37%
Monoclonal Plasma Cells
25%
Marrow
25%
Cell Apoptosis
25%
Biological Differences
25%
Multiple Myeloma Patients
25%
Cell Proliferation
12%
Malignant Transformation
12%
Apoptotic Rate
12%
Cell Growth
12%
Molecular Changes
12%
Angiogenesis
12%
Signaling Complex
12%
Current Treatment
12%
Fibroblast Growth Factor Receptor 1 (FGFR1)
12%
Bone Marrow
12%
FGF Receptor
12%
Malignant Cells
12%
Malignancy
12%
Molecular Identification
12%
Syndecan-1
12%
Plasma Cell Proliferative Disorder
12%
Disease Relapse
12%
Biological Changes
12%
Microvessel Density
12%
Malignant Disease
12%
Follow Current
12%
Differentiation Potential
12%
Receptor Signaling
12%
High Growth
12%
Receptor Expression
12%
Clinical Manifestations
12%
Activation System
12%
Overexpression
12%
In Vivo Activity
12%
Clonal Plasma Cells
12%
Plasma Cell Myeloma
12%
Specific Aims
12%
Immunology and Microbiology
Multiple Myeloma
100%
Myeloma Cell
100%
Immunoglobulin Producing Cell
90%
Monoclonal Immunoglobulinemia
72%
B Cell
54%
Fibroblast Growth Factor
54%
Proteoglycan
27%
Programmed Cell Death
18%
Myeloma Cell Line
9%
Cell Growth
9%
Apoptosis Rate
9%
Cell Proliferation
9%
Angiogenesis
9%
In Vitro
9%
Biochemistry, Genetics and Molecular Biology
Immunoglobulin Producing Cell
100%
B Cell
54%
Fibroblast Growth Factor
45%
Proteoglycan
27%
Heparan Sulfate
27%
Programmed Cell Death
18%
Fibroblast Growth Factor Receptor
18%
Angiogenesis
9%
Cell Proliferation
9%
Apoptosis Rate
9%
Syndecan
9%
Malignant Transformation
9%
Cell Growth
9%
Cytogenetics
9%